Prostate Cancer: An Update on Disease Pathogenesis and Drug Therapy
Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order
to see the Introduction page.
Over the last decade, much progress has been made in both the diagnosis and treatment of prostate cancer. One contributing factor is prostate-specific antigen (PSA) screening, which began in the 1980s. Widespread screening is controversial; however, because many early-stage cancers are slow-growing and treatment may result in more harm than benefit. Conversely, the curative treatments for early disease (i.e., surgery and radiation) offer improved success rates. Treatment options for advanced disease are also better - hormonal therapy is commonly started earlier in the course of the disease, and chemotherapeutic regimens have improved. Despite positive trends, prostate cancer remains the most common non-skin cancer in men, and the second most lethal tumor among men. About 1 in 6 men will be diagnosed with prostate cancer, but only 1 in 35 men will die of it.
This issue provides an overview of prostate cancer including risk factors, screening recommendations, symptoms, and diagnosis. Recommended treatment options to consider for early as well as more advanced cancer are discussed. A drug review focuses on the hormonal therapies (luteinizing hormone-releasing hormone [LHRH] agonists and antiandrogens) that are typically used for both localized prostate cancer and more advanced cancer. Strategies to manage common and serious adverse effects of these treatments are provided. Finally the Patient Connection offers answers to questions that patients often have about prostate cancer and hormonal therapies.
Publication Date: 01/01/2009
Expiration Date: 01/01/2012
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc.
The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and
is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased,
balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic
area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure
that every program presents information that is current, accurate, relevant to "real world" health care
providers, and written in an easy reading, "plain English" style.
Ellen Whipple Guthrie, Pharm.D., Clinical Assistant Professor, University of Georgia College of Pharmacy; Pharmacist, Children's Healthcare of Atlanta.
Dr. Guthrie reports no financial or personal relationship with any commercial interest producing, marketing, reselling,
or distributing a product or service that appears in this issue.
Guest Editorial Advisor
Jennifer Chang, PharmD, BCPS
This accredited program is targeted to pharmacists and nurses.
Goals & Objectives
At the conclusion of this program, participants will be able to:
- Describe the epidemiology and clinical presentation of prostate cancer.
- Discuss the recommendations from the American Cancer Society regarding annual PSA screening and digital rectal exam.
- Describe the recommended treatment options for early stage (localized) and advanced prostate cancer.
- Educate a patient about the potential benefits and common adverse effects of androgen deprivation therapy.
The Rx Consultant is a publication of Continuing Education Network, Inc.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a
provider of continuing pharmacy education.
Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.
ACPE Universal Activity Number: 428-0000-09-001-H01-P
Exam & Credit Statement Procedures
Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and
Editorial and Review Board
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA
Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA
Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA
Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System
Adjunct Clinical Professor
College of Pharmacy
Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Visiting Associate Professor and Lecturer
Samuel Merritt University
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
About the Rx Consultant
The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to
educate patients about drugs and manage drug therapy. The reader is responsible for confirming
the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)